The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Photodynamic therapy with Pd‐bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts
Open accessAbstract
Small cell carcinoma of the prostate (SCCP), although relatively rare, is the most aggressive variant of prostate cancer, currently with no successful treatment. It was therefore tempting to evaluate the response of this violent malignancy and its bone lesions to Pd‐Bacteriopheophorbide (TOOKAD)‐based photodynamic therapy (PDT), already proven by us to efficiently eradicate other aggressive non‐epithelial solid tumors. TOOKAD is a novel bacteriochlorophyll‐derived, second‐generation photosensitizer recently, developed by us for the treatment of bulky tumors. This photosensitizer is endowed with strong light absorbance (ϵ 0 ∼ 10 5 mol−1 cm−1) in the near infrared region (λ=763nm), allowing deep tissue penetration. The TOOKAD‐PDT protocol targets the tumor vasculature leading to inflammation, hypoxia, necrosis and tumor eradication. The sensitizer clears rapidly from the circulation within a few hours and does not accumulate in tissues, which is compatible with the treatment of localized tumor and isolated metastases. Briefly, male CD1‐nude mice were grafted with the human SCCP (WISH‐PC2) in 3 relevant anatomic locations: subcutaneous (representing tumor mass), intraosseous (representing bone metastases) and orthotopically within the murine prostate microenvironment. The PDT protocol consisted of i.v. administration of TOOKAD (4 mg/kg), followed by immediate illumination (650–800 nm) from a xenon light source or a diode laser emitting at 770 nm. Controls included untreated animals or animals treated with light or TOOKAD alone. Tumor volume, human plasma chromogranin A levels, animal well being and survival were used as end points. In addition, histopathology and immunohistochemistry were used to define the tumor response. Subcutaneous tumors exhibited complete healing within 28–40 days, reaching an overall long‐term cure rate of 69%, followed for 90 days after PDT. Intratibial WISH‐PC2 lesions responded with complete tumor elimination in 50% of the treated mice at 70–90 days after PDT as documented histologically. The response of the orthotopic model was also analyzed histologically with similar results. The study with this model suggests that TOOKAD‐based PDT can reach large tumors and is a feasible, efficient and well‐tolerated approach for minimally invasive treatment of local and disseminated SCCP. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free Radicals in Biology and Medicine
Halliwell, B., & Gutteridge, J. M. C. (2015) · doi:10.1093/acprof:oso/9780198717478.001.0001 · Cited by 8,990
Cited by
O’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
In Vitro Demonstration of the Heavy-Atom Effect for Photodynamic Therapy
Gorman, A., Killoran, J., O'Shea, C., Kenna, T., Gallagher, W. M., & O'Shea, D. F. (2004) · Journal of the American Chemical Society · doi:10.1021/ja047649e · Cited by 917
Photodynamic therapy (PDT) of cancer: from local to systemic treatment
Dabrowski, J. M., & Arnaut, L. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00132c · Cited by 501
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
Features of third generation photosensitizers used in anticancer photodynamic therapy: Review
Mfouo-Tynga, I. S., Dias, L. D., Inada, N. M., & Kurachi, C. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.102091 · Cited by 260
Metadata
- Authors
- Koudinova, N. V., Pinthus, J. H., Brandis, A., Brenner, O., Bendel, P., Ramon, J., Eshhar, Z., Scherz, A., & Salomon, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-02-13
- Volume
- 104
- Issue
- 6
- Pages
- 782-789
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2011528765
- Cited by
- 199
- References
- 1
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.